


Scientists reveal new TEV-mediated α PD-L1-specific therapy resistance mechanism

October 31 2022



TEV PD-L1 competes with PD-L1 on tumor cells to bind α PD-L1. **a, b** MC38-EVs and PC3-EVs (1 μ g) (**a**) or MC38 and PC3 cells (1 $\times 10^5$) (**b**) were coincubated with the indicated doses of α PD-L1 in 100 μ l of medium for 30 min. Then, PD-L1 on EVs (**a**) or cells (**b**) was detected by flow cytometry. **c** A total of 1 $\times 10^5$ MC38 and PC3 cells were coincubated with α PD-L1_{CV} with or without the corresponding EVs at the indicated doses in 100 μ l of medium for 30 min. Then, PD-L1 on the cells was detected by flow cytometry. **d, e** A total of 1 $\times 10^5$ MC38 cells were coincubated with α PD-L1_{CV} (**d**) or α PD-L1_{Exe} (**e**) in the presence of the indicated doses of MC38 *Pd11*^{-/-}-EVs (**d**) or MC38-EVs (**e**) in 100 μ l of medium for 30 min. Then, PD-L1 on MC38 cells was detected by flow cytometry. The α PD-L1 for coincubation and detection recognizes the same epitope in PD-L1. Representative results from three independent experiments are shown ($n = 3$). * P

Citation: Scientists reveal new TEV-mediated α PD-L1-specific therapy resistance mechanism (2022, October 31) retrieved 3 May 2024 from <https://medicalxpress.com/news/2022-10-scientists-reveal-tev-mediated-pd-l1-specific-therapy.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.